查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
RNA 治疗临床试验市场 - 成长、未来前景、竞争分析，2023-2031
市场调查报告书
商品编码
1340134

RNA 治疗临床试验市场 - 成长、未来前景、竞争分析，2023-2031

RNA Therapy Clinical Trials Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031
出版日期: | 出版商: Acute Market Reports | 英文 110 Pages | 商品交期: 最快1-2个工作天内

价格

由于基于 RNA 的治疗方法的进步以及标靶和个人化治疗的潜力，RNA 治疗临床试验市场预计在 2023 年至 2031 年预测期内将以 4% 的复合年增长率增长。RNA疗法利用核糖核酸（RNA）分子靶向特定基因并调节蛋白质产生，为治疗多种疾病（包括癌症、遗传性疾病和传染病）提供了有希望的机会。随着更多基于 RNA 的疗法通过临床试验并走向商业化，市场收入预计将继续呈上升趋势。对个人化医疗的需求不断增长，有可能治疗以前无法治疗的疾病，也促进了市场的扩张。RNA 治疗领域正在进行的临床试验对于评估这些创新疗法的安全性和有效性至关重要。随着更多临床数据的出现，监管机构对基于 RNA 的药物的批准可能会增加，为临床实践中更广泛的采用铺平道路。总而言之，在基于RNA 的疗法彻底改变疾病治疗并提供个人化有针对性的医疗保健方法的潜力的推动下，RNA 疗法临床试验市场呈现出令人印象深刻的收入增长和充满希望的复合年增长率。随着临床试验的进展和更多基于 RNA 的药物进入市场，RNA 疗法将对医学和患者护理的未来产生重大影响。

RNA治疗技术的进展

RNA治疗技术的进步是支持RNA治疗临床试验市场成长的主要因素。更稳定、更有效的递送系统（例如脂质奈米颗粒和病毒载体）的开发改善了基于 RNA 的治疗药物向目标组织和细胞的递送。此外，RNA合成和修饰技术的创新正在提高RNA分子的稳定性和特异性，使它们能够更有效地针对致病基因。这些技术进步扩大了 RNA 疗法的潜在应用，并导致探索其在治疗多种疾病中的用途的临床试验激增。《Nature Communications》上发表的一项研究报告了使用脂质奈米粒子成功递送 mRNA 疗法，显示出临床前模型中稳定性和治疗效果的改善。《Journal of Controlled Release》上发表的另一项研究强调了使用自扩增 mRNA 作为疫苗平台，并在动物模型中证明了对感染的强大免疫反应。这些例子显示了 RNA 疗法的技术进步如何促进临床试验的进展并增加治疗成功的可能性。

慢性病和遗传性疾病盛行率上升

慢性病和遗传疾病的盛行率不断上升，刺激了对创新和标靶治疗的需求，并推动了 RNA 治疗临床试验的成长。基于 RNA 的疗法透过针对特定的致病基因和调节蛋白质的产生，提供了解决以前无法治疗的疾病的潜力。癌症、罕见遗传疾病和神经退化性疾病等疾病正在成为基于 RNA 的治疗的重要标靶。迫切需要找到针对这些疾病的有效治疗方法，导致研究 RNA 疗法的安全性和有效性的临床试验激增，将其定位为未来医疗干预的有希望的途径。美国癌症协会报告称，癌症仍然是全世界死亡的主要原因之一，这促使人们大力开展研究和临床工作，以开发标靶疗法，包括基于 RNA 的方法。同样，国家罕见疾病组织 (NORD) 等组织也强调罕见遗传疾病创新疗法的必要性，并增加了对 RNA 疗法临床试验的兴趣和投资。

支持性监管环境

基于 RNA 的疗法的支持性监管环境在推动临床试验市场的成长中发挥关键作用。美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构已经建立了框架和加速途径，以加快 RNA 疗法的开发和批准。这些途径将加速有前景的基于 RNA 的疗法的临床开发和审查，减少将这些疗法推向市场的时间和成本。监管支援正在鼓励更多製药和生物技术公司投资 RNA 疗法开发，并为扩大该领域的临床试验做出贡献。FDA 批准了第一个基于 ASO 的基于 RNA 的治疗药物，用于治疗特定的遗传疾病，这证明了 RNA 治疗药物的支持性监管环境。此外，针对基于 RNA 的治疗的具体监管指南和加速途径的製定表明了监管机构促进该领域创新的承诺。

交付和定位挑战

影响 RNA 疗法临床试验市场的重要限制因素之一是与基于 RNA 的疗法的递送和标靶相关的挑战。RNA 分子本质上不稳定，容易被细胞内酵素降解，这会限制其功效和治疗潜力。此外，有效地将 RNA 疗法传递到特定的目标组织和细胞仍然是一个主要障碍。递送系统必须保护 RNA 分子免于降解，让它们穿过生物屏障，并允许有效地摄取到目标细胞中。此外，实现精确标靶对于避免脱靶效应和潜在副作用至关重要。开发安全有效的递送载体，将 RNA 治疗药物精确地递送至所需的作用位点，仍然是 RNA 治疗领域中一个复杂且持续的挑战。《Journal of Controlled Release》上发表的一项研究强调了使用奈米粒子提供基于 RNA 的治疗方法所面临的挑战，并强调了稳定性和控释方面的问题。此外，《Nature Reviews Drug Discovery》上发表的一篇综述强调，递送和标靶障碍是 RNA 疗法临床应用的关键瓶颈，影响治疗效果和整体成功。这些例子强调了解决与递送和标靶相关的挑战的重要性，以最大限度地发挥基于 RNA 的疗法在临床试验中的潜力。

信使 RNA (mRNA) 领域继续主导成长和收入

在 RNA 治疗临床试验市场的各个模式领域中，信使 RNA (mRNA) 领域预计将在 2023-2031 年预测期内表现出最高的复合年增长率，并在 2022 年实现最高收入。我做到了。基于 mRNA 的疗法前景广阔，因为它们直接编码体内的特定蛋白质，为疫苗开发、癌症免疫疗法和蛋白质替代疗法提供了潜在的应用。mRNA 引发针对病原体的标靶免疫反应的能力正在引起人们对探索其治疗潜力的临床试验的极大兴趣和投资，基于 mRNA 的 COVID-19 疫苗的成功开发证明了这一点。此外，反义疗法领域的复合年增长率和收入也显示出显着成长。反义疗法透过针对特定的 RNA 分子来调节蛋白质的产生，使其特别适合治疗遗传性疾病和某些类型的癌症。反义疗法的发展正在迅速进展，多项临床试验已显示出针对多种疾病的潜在功效。RNA干扰（RNAi）领域是RNA治疗临床试验中发展缓慢但不可或缺的疗法。基于 RNAi 的疗法抑制特定基因的表达，为标靶致病基因提供了一种有前景的方法。最后，寡核甘酸、非反义、非 RNAi 领域也在稳定成长，包括不属于传统反义或 RNAi 类别的基于 RNA 的创新疗法。

从临床试验阶段来看，III期试验占市场主导地位

在RNA疗法临床试验市场中，临床试验阶段是决定RNA疗法进展和成功的关键因素。在各阶段中，III期试验部分预计在2023-2031年预测期间呈现最高复合年增长率，并在2022年产生最高收入。III 期试验旨在纳入更多患者，并评估 RNA 疗法与现有标准疗法或安慰剂相比的安全性和有效性。III 期试验的正面结果将导致基于 RNA 的疗法获得监管批准和商业化。因此，III期临床试验的高获利和高成长得益于药厂在后期临床开发上的大量投资。此外，二期试验的复合年增长率和收入也出现了显着增长。II 期试验评估 RNA 疗法在更大患者群体中的治疗效果和剂量，并为支持 RNA 疗法向 III 期试验的过渡提供重要数据。随着基于 RNA 的疗法的临床开发的进展，对 II 期试验的需求增加，促进了市场的惊人成长。I 期试验（包括在少数健康志愿者中进行 RNA 疗法的早期试验）显示出适度的增长。这些临床试验的重点是评估RNA疗法的安全性和剂量范围，并为后续步骤奠定基础发挥至关重要的作用。最后，第四阶段试验正在稳定成长。IV 期试验，也称为上市后监测试验，评估 RNA 疗法在现实临床环境中的长期安全性和有效性。这些试验提供了有关基于 RNA 的疗法在受控临床试验环境之外的性能的宝贵数据，并确保其在广泛使用期间持续安全性和有效性。总体而言，III 期试验的复合年增长率和销售额最高，反映出它们在基于 RNA 的疗法的成功商业化和采用中发挥的关键作用。

亚太地区在预测期内蕴藏着巨大的机会

北美成为表现突出的市场，RNA 治疗临床试验的销售百分比最高。该地区强大的市场地位归功于主要製药和生物技术公司的存在，这些公司正在大力投资基于 RNA 的疗法。此外，成熟的医疗基础设施、支持性监管环境和慢性病的高盛行率正在推动北美对 RNA 治疗临床试验的需求。同时，亚太地区的RNA治疗临床试验市场复合年增长率(CAGR)最高。该地区的成长得益于政府加强临床研究措施、医疗保健支出增加以及对精准医疗的日益关注等因素。此外，亚太地区庞大且多样化的患者群体为研究基于 RNA 的疗法在各种疾病中的有效性和安全性的临床试验提供了巨大的机会。欧洲的收入排名第二，仅次于北美，其强大的研究基础设施和对创新疗法日益增长的兴趣推动了 RNA 疗法临床试验的需求。此外，由于医疗基础设施的改善和医学研究投资的增加，中东、非洲和拉丁美洲地区的 RNA 治疗临床试验也出现了小幅增长。

研发投资在大公司的重要性日益增加

RNA治疗临床试验市场在製药和生物技术行业的主要参与者中竞争非常激烈。这些公司处于开发基于 RNA 的创新疗法并进行临床试验以评估其安全性和有效性的前沿。这项竞争格局的主要参与者包括 Moderna Therapeutics、BioNTech SE、Arrowhead Pharmaceuticals、Alnylam Pharmaceuticals 和 Ionis Pharmaceuticals。这些公司已成为 RNA 治疗的领导者，拥有针对多种疾病（包括癌症、遗传性疾病和传染病）的基于 RNA 的治疗药物的强大产品线。在这种竞争环境中，领先公司采取了多种策略来巩固自己的地位并推动 RNA 治疗临床试验的进步。其中一项关键策略着重于研发（R&D）投资。领先的公司正在投入大量资源来发现和开发基于 RNA 的新型疗法。这包括投资尖端 RNA 合成和递送技术、提高 RNA 分子的稳定性和特异性，以及探索 mRNA 和 RNA 干扰 (RNAi) 疗法等新疗法。此外，市场参与者也在探索新兴市场的机会，并寻求扩大其全球足迹。亚太地区由于其庞大的患者群体和不断增加的医疗保健投资而具有巨大的成长潜力。主要参与者正在这些地区建立合作伙伴关係并进行临床试验，以满足对基于 RNA 的创新疗法不断增长的需求。总体而言，RNA 治疗临床试验市场的竞争趋势的特征是强大的研发投资、策略联盟、监管参与以及对全球扩张的关注。该市场的领先公司致力于推动 RNA 治疗领域的发展，将有前景的临床试验结果转化为经批准且商业上成功的治疗方法。随着临床试验的进展以及更多基于RNA的药物走向商业化，RNA治疗临床试验市场将持续成长和变革，为多种疾病的个人化和标靶治疗的进步做出贡献，令人期待。

目录

第一章 前言

  • 报告内容
    • 报告目的
    • 目标听众
    • 主要提供产品
  • 市场细分
  • 调查方法
    • 第一阶段—二次调查
    • 第二阶段-初步调查
    • 第三阶段-专家评审
    • 先决条件
    • 采取的方法

第二章执行摘要

第三章 RNA治疗临床试验市场：竞争分析

  • 主要供应商的市场地位
  • 供应商采取的策略
  • 主要产业战略
  • 等级分析：2022 年与 2031 年

第四章 RNA治疗临床试验市场：宏观分析与市场动态

  • 介绍
  • 2021-2031年全球RNA治疗临床试验市场价值
  • 市场动态
    • 市场驱动力
    • 市场製约因素
    • 主要问题
    • 主要机会
  • 促进因素和抑制因素的影响分析
  • 跷跷板分析

第五章 RNA 治疗临床试验市场：依模式 2021-2031

  • 市场概况
  • 成长/利润分析：2022 年与 2031 年
  • 市场细分
    • RNA干扰
    • 反义疗法
    • 信差核糖核酸
    • 寡核甘酸非反义非RNAi

第六章 RNA 治疗临床试验市场：依临床试验阶段划分 2021-2031

  • 市场概况
  • 成长/利润分析：2022 年与 2031 年
  • 市场细分
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段

第七章 RNA 治疗临床试验市场：依治疗领域 2021-2031

  • 市场概况
  • 成长/利润分析：2022 年与 2031 年
  • 市场细分
    • 罕见疾病
    • 抗感染
    • 抗癌剂
    • 神经系统
    • 消化系统/代谢系统
    • 肌肉骨骼系统
    • 心血管、呼吸系统
    • 情怀
    • 其他

第八章北美RNA治疗临床试验市场2021-2031

  • 市场概况
  • RNA 治疗临床试验市场：依模式 2021-2031
  • RNA 治疗临床试验市场：依临床试验阶段 2021-2031
  • RNA 治疗临床试验市场：依治疗领域 2021-2031
  • RNA 治疗临床试验市场：依地区划分 2021-2031
    • 北美
      • 美国
      • 加拿大
      • 其他北美

第九章英国及欧盟RNA治疗临床试验市场2021-2031

  • 市场概况
  • RNA 治疗临床试验市场：依模式 2021-2031
  • RNA 治疗临床试验市场：依临床试验阶段 2021-2031
  • RNA 治疗临床试验市场：依治疗领域 2021-2031
  • RNA 治疗临床试验市场：依地区划分 2021-2031
    • 英国和欧盟
      • 英国
      • 德国
      • 西班牙
      • 意大利
      • 法国
      • 欧洲其他地区

第十章亚太RNA治疗临床试验市场2021-2031

  • 市场概况
  • RNA 治疗临床试验市场：依模式 2021-2031
  • RNA 治疗临床试验市场：依临床试验阶段 2021-2031
  • RNA 治疗临床试验市场：依治疗领域 2021-2031
  • RNA 治疗临床试验市场：依地区划分 2021-2031
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 亚太其他地区

第十一章拉丁美洲RNA治疗临床试验市场2021-2031

  • 市场概况
  • RNA 治疗临床试验市场：依模式 2021-2031
  • RNA 治疗临床试验市场：依临床试验阶段 2021-2031
  • RNA 治疗临床试验市场：依治疗领域 2021-2031
  • RNA 治疗临床试验市场：依地区划分 2021-2031
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 其他拉丁美洲地区

第十二章中东与非洲RNA治疗临床试验市场2021-2031

  • 市场概况
  • RNA 治疗临床试验市场：依模式 2021-2031
  • RNA 治疗临床试验市场：依临床试验阶段 2021-2031
  • RNA 治疗临床试验市场：依治疗领域 2021-2031
  • RNA 治疗临床试验市场：依地区划分 2021-2031
    • 中东/非洲
      • GCC
      • 非洲
      • 其他中东/非洲地区

第十三章公司简介

  • Moderna Therapeutics
  • BioNTech SE
  • Arrowhead Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Ionis Pharmaceuticals
  • 其他主要公司
Product Code: 139742-07-23

The RNA therapy clinical trials market is expected to witness a CAGR of 4% during the forecast period of 2023 to 2031, driven by advancements in RNA-based therapeutic approaches and the potential for targeted and personalized treatments. RNA therapy involves the use of ribonucleic acid (RNA) molecules to target specific genes and modulate protein production, offering promising opportunities for treating various diseases, including cancer, genetic disorders, and infectious diseases. The market's revenue is expected to continue its upward trajectory as more RNA-based therapies progress through clinical trials and move toward commercialization. The potential to address previously untreatable diseases and the growing demand for personalized medicine has also contributed to the market's expansion. The ongoing clinical trials in the RNA therapy field are essential for evaluating the safety and efficacy of these innovative therapies. As more clinical data become available, regulatory approvals for RNA-based drugs are likely to increase, paving the way for their wider adoption in clinical practice. In conclusion, the RNA therapy clinical trials market has shown impressive revenue growth and a promising CAGR, driven by the potential of RNA-based therapies to revolutionize disease treatment and offer personalized, targeted approaches to healthcare. As clinical trials progress and more RNA-based drugs enter the market, RNA therapy is poised to have a significant impact on the future of medicine and patient care.

Advancements in RNA Therapeutic Technologies

Advancements in RNA therapeutic technologies have been a major driver behind the growth of the RNA therapy clinical trials market. The development of more stable and efficient delivery systems, such as lipid nanoparticles and viral vectors, has improved the delivery of RNA-based therapies to target tissues and cells. Additionally, innovations in RNA synthesis and modification techniques have enhanced the stability and specificity of RNA molecules, enabling more effective targeting of disease-causing genes. These technological advancements have expanded the potential applications of RNA therapies, leading to a surge in clinical trials exploring their use in treating a wide range of diseases. A study published in Nature Communications reported on the successful delivery of mRNA therapeutics using lipid nanoparticles, showing increased stability and therapeutic efficacy in preclinical models. Another study in the Journal of Controlled Release highlighted the use of self-amplifying mRNA as a vaccine platform, demonstrating robust immune responses against infectious diseases in animal models. These examples demonstrate how technological advancements in RNA therapeutics are driving progress in clinical trials and increasing the potential for successful treatments.

Rising Prevalence of Chronic and Genetic Diseases

The increasing prevalence of chronic and genetic diseases has fueled the demand for innovative and targeted therapies, thus driving the growth of RNA therapy clinical trials. RNA-based therapies offer the potential to address previously untreatable diseases by targeting specific disease-causing genes and modulating protein production. Conditions such as cancer, rare genetic disorders, and neurodegenerative diseases have emerged as key targets for RNA-based therapeutics. The urgency to find effective treatments for these diseases has led to a surge in clinical trials investigating the safety and efficacy of RNA therapies, positioning them as a promising avenue for future medical interventions. The American Cancer Society reported that cancer remains one of the leading causes of death worldwide, leading to significant research and clinical efforts to develop targeted therapies, including RNA-based approaches. Similarly, organizations such as the National Organization for Rare Disorders (NORD) emphasize the need for innovative therapies for rare genetic diseases, driving increased interest and investment in RNA therapy clinical trials.

Supportive Regulatory Environment

The supportive regulatory environment for RNA-based therapies has played a crucial role in driving the growth of the clinical trials market. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established frameworks and expedited pathways to facilitate the development and approval of RNA therapies. These pathways allow for accelerated clinical development and review of promising RNA-based treatments, reducing the time and cost required to bring these therapies to the market. The regulatory support has encouraged more pharmaceutical and biotechnology companies to invest in RNA therapy development and has contributed to the expansion of clinical trials in this field. The FDA's approval of the first RNA-based therapeutic, an ASO-based drug for the treatment of a specific genetic disorder, stands as a testament to the supportive regulatory environment for RNA therapies. Additionally, the creation of regulatory guidelines and expedited pathways specifically tailored for RNA-based therapeutics demonstrates the commitment of regulatory agencies to foster innovation in this field.

Challenges in Delivery and Targeting

One significant restraint impacting the RNA therapy clinical trials market is the challenges associated with the delivery and targeting of RNA-based therapeutics. RNA molecules are inherently unstable and susceptible to degradation by cellular enzymes, which can limit their efficacy and therapeutic potential. Moreover, effectively delivering RNA therapies to specific target tissues and cells poses a significant obstacle. Delivery systems need to protect RNA molecules from degradation, navigate biological barriers, and ensure efficient uptake by the intended cells. Additionally, achieving precise targeting is essential to avoid off-target effects and potential adverse reactions. Developing safe and effective delivery vehicles that can precisely deliver RNA therapies to the desired sites of action remains a complex and ongoing challenge in the field of RNA therapeutics. A study published in the Journal of Controlled Release highlighted the difficulties in delivering RNA-based therapeutics using nanoparticles, where issues of stability and controlled release were identified. Furthermore, a review published in Nature Reviews Drug Discovery emphasized that delivery and targeting hurdles are critical bottlenecks in the clinical translation of RNA therapies, impacting their therapeutic efficacy and overall success. These examples highlight the importance of addressing the challenges associated with delivery and targeting to unlock the full potential of RNA-based therapies in clinical trials.

Messenger RNA (mRNA) Segment to Continue Dominating Growth and Revenues

Among the various modality segments in the RNA therapy clinical trials market, the Messenger RNA (mRNA) segment is expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and generated the highest revenue in 2022. mRNA-based therapies hold immense promise as they directly encode specific proteins in the body, offering potential applications in vaccine development, cancer immunotherapy, and protein replacement therapies. The ability of mRNA to trigger a targeted immune response against pathogens, such as seen with the successful development of mRNA-based COVID-19 vaccines, has driven significant interest and investment in clinical trials exploring its therapeutic potential. Additionally, the Antisense therapy segment has also shown substantial growth in both CAGR and revenue. Antisense therapies work by targeting specific RNA molecules to modulate protein production, making them particularly suitable for treating genetic disorders and certain types of cancer. The development of Antisense therapies has progressed rapidly, with several clinical trials showcasing their potential efficacy in various diseases. The RNA interference (RNAi) segment, while experiencing moderate growth, remains an essential modality in RNA therapy clinical trials. RNAi-based therapies interfere with the expression of specific genes, offering a promising approach to target disease-causing genes. Lastly, the Oligonucleotide, non-antisense, non-RNAi segment has also witnessed steady growth, encompassing other innovative RNA-based therapeutic modalities that do not fit within the traditional antisense or RNAi categories.

Phase III Trials to Dominate the Market by Clinical Trial Phase

In the RNA therapy clinical trials market, the Clinical Trials Phase is a crucial factor in determining the progression and success of RNA-based therapies. Among the various phases, the Phase III trials segment is expected to exhibit the highest CAGR during the forecast period of 2023 to 2031 and generated the highest revenue in 2022. Phase III trials involve a larger population of patients and are designed to evaluate the safety and efficacy of RNA therapies in comparison to existing standard treatments or placebos. Positive results from Phase III trials are essential for obtaining regulatory approval and commercialization of RNA-based therapies. Consequently, the high revenue and growth in Phase III trials can be attributed to the significant investments made by pharmaceutical companies in late-stage clinical development. Additionally, Phase II trials have also experienced substantial growth in both CAGR and revenue. Phase II trials assess the therapeutic efficacy and dosing of RNA therapies in a larger patient group, providing critical data to support the advancement of RNA therapeutics into Phase III trials. As RNA-based therapies progress through clinical development, the demand for Phase II trials has increased, contributing to their impressive growth in the market. Phase I trials, which involve the initial testing of RNA therapies in a small group of healthy volunteers, have shown moderate growth. These trials focus on evaluating the safety and dosage range of RNA therapies and play a pivotal role in laying the groundwork for subsequent phases. Lastly, Phase IV trials have experienced steady growth. Also known as post-marketing surveillance trials, Phase IV trials assess the long-term safety and effectiveness of RNA therapies in a real-world setting. These trials provide valuable data on the performance of RNA-based therapies beyond the controlled clinical trial environment, ensuring their continued safety and efficacy during widespread use. Overall, Phase III trials stand out with the highest CAGR and revenue, reflecting their critical role in the successful commercialization and adoption of RNA-based therapies.

APAC to Promise Significant Opportunities during the Forecast Period

North America has emerged as a prominent market, showcasing the highest revenue percentage in RNA therapy clinical trials. The region's strong market position can be attributed to the presence of leading pharmaceutical and biotechnology companies with significant investments in RNA-based therapies. Additionally, well-established healthcare infrastructure, a supportive regulatory environment, and a high prevalence of chronic diseases drive the demand for RNA therapy clinical trials in North America. On the other hand, Asia-Pacific has experienced the highest Compound Annual Growth Rate (CAGR) in the RNA therapy clinical trials market. The region's growth can be attributed to factors such as increasing government initiatives to promote clinical research, rising healthcare expenditure, and a growing focus on precision medicine. Moreover, the large and diverse patient population in Asia-Pacific provides a substantial opportunity for clinical trials investigating the efficacy and safety of RNA-based therapies in different disease contexts. Europe follows North America closely in terms of revenue generation, with a robust research infrastructure and growing interest in innovative therapies fueling the demand for RNA therapy clinical trials. Furthermore, the Middle East and Africa, and Latin America regions are also witnessing moderate growth in RNA therapy clinical trials, driven by improving healthcare infrastructure and rising investments in medical research.

R&D Investments to Become Crucial among the Top Market Players

The RNA therapy clinical trials market is witnessing intense competition among top players in the pharmaceutical and biotechnology industries. These companies are at the forefront of developing innovative RNA-based therapies and conducting clinical trials to assess their safety and efficacy. Some of the key players in this competitive landscape include Moderna Therapeutics, BioNTech SE, Arrowhead Pharmaceuticals, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals, among others. These companies have established themselves as leaders in the RNA therapy field, with a strong pipeline of RNA-based therapeutics targeting various diseases, including cancer, genetic disorders, and infectious diseases. In this competitive environment, key players are employing several strategies to strengthen their position and drive advancements in RNA therapy clinical trials. One of the primary strategies is focused on research and development (R&D) investment. Leading companies are dedicating substantial resources to discovering and developing novel RNA-based therapies. This includes investing in cutting-edge RNA synthesis and delivery technologies, enhancing the stability and specificity of RNA molecules, and exploring new therapeutic modalities, such as mRNA and RNA interference (RNAi) therapies. Furthermore, market players are also exploring opportunities in emerging markets to expand their global footprint. Asia-Pacific, in particular, presents significant growth potential, with a large patient population and increasing healthcare investments. Key players are establishing partnerships and conducting clinical trials in these regions to tap into the rising demand for innovative RNA-based therapies. Overall, the competitive trends in the RNA therapy clinical trials market are characterized by robust R&D investments, strategic collaborations, regulatory engagements, and a focus on global expansion. The key players in the market are committed to advancing the field of RNA therapy and translating promising clinical trial results into approved and commercially successful therapies. As clinical trials progress and more RNA-based drugs move towards commercialization, the RNA therapy clinical trials market is expected to witness further growth and transformation, contributing to the advancement of personalized and targeted therapies for a wide range of diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofRNA Therapy Clinical Trials market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the RNA Therapy Clinical Trials market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Modality

  • RNA interference
  • Antisense therapy
  • Messenger RNA
  • Oligonucleotide, non-antisense, non-RNAi

Clinical Trials Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Therapeutic Areas

  • Rare Diseases
  • Anti-infective
  • Anticancer
  • Neurological
  • Alimentary/Metabolic
  • Musculoskeletal
  • Cardiovascular Respiratory
  • Sensory
  • Others

Region Segment (2021-2031; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of RNA Therapy Clinical Trials market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2031.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the RNA Therapy Clinical Trials market?
  • Which is the largest regional market for RNA Therapy Clinical Trials market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving RNA Therapy Clinical Trials market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the RNA Therapy Clinical Trials market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global RNA Therapy Clinical Trials Market
  • 2.2. Global RNA Therapy Clinical Trials Market, By Modality, 2022 (US$ Million)
  • 2.3. Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022 (US$ Million)
  • 2.4. Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022 (US$ Million)
  • 2.5. Global RNA Therapy Clinical Trials Market, By Geography, 2022 (US$ Million)
  • 2.6. Attractive Investment Proposition by Geography, 2022

3. RNA Therapy Clinical Trials Market: Competitive Analysis

  • 3.1. Market Positioning of Key RNA Therapy Clinical Trials Market Vendors
  • 3.2. Strategies Adopted by RNA Therapy Clinical Trials Market Vendors
  • 3.3. Key Industry Strategies
  • 3.4. Tier Analysis 2022 Versus 2031

4. RNA Therapy Clinical Trials Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global RNA Therapy Clinical Trials Market Value, 2021 - 2031, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis

5. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 5.3. Market Segmentation
    • 5.3.1. RNA interference
    • 5.3.2. Antisense therapy
    • 5.3.3. Messenger RNA
    • 5.3.4. Oligonucleotide, non-antisense, non-RNAi

6. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 6.3. Market Segmentation
    • 6.3.1. Phase I
    • 6.3.2. Phase II
    • 6.3.3. Phase III
    • 6.3.4. Phase IV

7. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

  • 7.1. Market Overview
  • 7.2. Growth & Revenue Analysis: 2022 Versus 2031
  • 7.3. Market Segmentation
    • 7.3.1. Rare Diseases
    • 7.3.2. Anti-infective
    • 7.3.3. Anticancer
    • 7.3.4. Neurological
    • 7.3.5. Alimentary/Metabolic
    • 7.3.6. Musculoskeletal
    • 7.3.7. Cardiovascular Respiratory
    • 7.3.8. Sensory
    • 7.3.9. Others

8. North America RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 8.1. Market Overview
  • 8.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 8.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 8.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 8.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 8.5.1.North America
      • 8.5.1.1. U.S.
        • 8.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 8.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 8.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 8.5.1.2. Canada
        • 8.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 8.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 8.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 8.5.1.3. Rest of North America
        • 8.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 8.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 8.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

9. UK and European Union RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 9.1. Market Overview
  • 9.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 9.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 9.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 9.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 9.5.1.UK and European Union
      • 9.5.1.1. UK
        • 9.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.2. Germany
        • 9.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.3. Spain
        • 9.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.4. Italy
        • 9.5.1.4.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.4.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.4.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.5. France
        • 9.5.1.5.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.5.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.5.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 9.5.1.6. Rest of Europe
        • 9.5.1.6.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 9.5.1.6.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 9.5.1.6.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

10. Asia Pacific RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 10.1. Market Overview
  • 10.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 10.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 10.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 10.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 10.5.1.Asia Pacific
      • 10.5.1.1. China
        • 10.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.2. Japan
        • 10.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.3. India
        • 10.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.4. Australia
        • 10.5.1.4.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.4.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.4.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.5. South Korea
        • 10.5.1.5.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.5.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.5.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 10.5.1.6. Rest of Asia Pacific
        • 10.5.1.6.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 10.5.1.6.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 10.5.1.6.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

11. Latin America RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 11.1. Market Overview
  • 11.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 11.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 11.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 11.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 11.5.1.Latin America
      • 11.5.1.1. Brazil
        • 11.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 11.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 11.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 11.5.1.2. Mexico
        • 11.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 11.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 11.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 11.5.1.3. Rest of Latin America
        • 11.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 11.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 11.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

12. Middle East and Africa RNA Therapy Clinical Trials Market, 2021-2031, USD (Million)

  • 12.1. Market Overview
  • 12.2. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
  • 12.3. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
  • 12.4. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
  • 12.5.RNA Therapy Clinical Trials Market: By Region, 2021-2031, USD (Million)
    • 12.5.1.Middle East and Africa
      • 12.5.1.1. GCC
        • 12.5.1.1.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 12.5.1.1.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 12.5.1.1.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 12.5.1.2. Africa
        • 12.5.1.2.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 12.5.1.2.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 12.5.1.2.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)
      • 12.5.1.3. Rest of Middle East and Africa
        • 12.5.1.3.1. RNA Therapy Clinical Trials Market: By Modality, 2021-2031, USD (Million)
        • 12.5.1.3.2. RNA Therapy Clinical Trials Market: By Clinical Trials Phase, 2021-2031, USD (Million)
        • 12.5.1.3.3. RNA Therapy Clinical Trials Market: By Therapeutic Areas, 2021-2031, USD (Million)

13. Company Profile

  • 13.1. Moderna Therapeutics
    • 13.1.1. Company Overview
    • 13.1.2. Financial Performance
    • 13.1.3. Product Portfolio
    • 13.1.4. Strategic Initiatives
  • 13.2. BioNTech SE
    • 13.2.1. Company Overview
    • 13.2.2. Financial Performance
    • 13.2.3. Product Portfolio
    • 13.2.4. Strategic Initiatives
  • 13.3. Arrowhead Pharmaceuticals
    • 13.3.1. Company Overview
    • 13.3.2. Financial Performance
    • 13.3.3. Product Portfolio
    • 13.3.4. Strategic Initiatives
  • 13.4. Alnylam Pharmaceuticals
    • 13.4.1. Company Overview
    • 13.4.2. Financial Performance
    • 13.4.3. Product Portfolio
    • 13.4.4. Strategic Initiatives
  • 13.5. Ionis Pharmaceuticals
    • 13.5.1. Company Overview
    • 13.5.2. Financial Performance
    • 13.5.3. Product Portfolio
    • 13.5.4. Strategic Initiatives
  • 13.6. Other Notable Players
    • 13.6.1. Company Overview
    • 13.6.2. Financial Performance
    • 13.6.3. Product Portfolio
    • 13.6.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 2 Global RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 3 Global RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 4 North America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 5 North America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 6 North America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 7 U.S. RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 8 U.S. RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 9 U.S. RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 10 Canada RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 11 Canada RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 12 Canada RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 13 Rest of North America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 14 Rest of North America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 15 Rest of North America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 16 UK and European Union RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 17 UK and European Union RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 18 UK and European Union RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 19 UK RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 20 UK RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 21 UK RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 22 Germany RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 23 Germany RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 24 Germany RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 25 Spain RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 26 Spain RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 27 Spain RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 28 Italy RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 29 Italy RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 30 Italy RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 31 France RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 32 France RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 33 France RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 34 Rest of Europe RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 35 Rest of Europe RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 36 Rest of Europe RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 37 Asia RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 38 Asia RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 39 Asia RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 40 China RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 41 China RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 42 China RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 43 Japan RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 44 Japan RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 45 Japan RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 46 India RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 47 India RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 48 India RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 49 Australia RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 50 Australia RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 51 Australia RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 52 South Korea RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 53 South Korea RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 54 South Korea RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 55 Latin America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 56 Latin America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 57 Latin America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 58 Brazil RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 59 Brazil RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 60 Brazil RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 61 Mexico RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 62 Mexico RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 63 Mexico RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 64 Rest of Latin America RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 65 Rest of Latin America RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 66 Rest of Latin America RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 67 Middle East and Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 68 Middle East and Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 69 Middle East and Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 70 GCC RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 71 GCC RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 72 GCC RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 73 Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 74 Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 75 Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)
  • TABLE 76 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Modality, 2021-2031, USD (Million)
  • TABLE 77 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Clinical Trials Phase, 2021-2031, USD (Million)
  • TABLE 78 Rest of Middle East and Africa RNA Therapy Clinical Trials Market By Therapeutic Areas, 2021-2031, USD (Million)

List of Figures

  • FIG. 1 Global RNA Therapy Clinical Trials Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global RNA Therapy Clinical Trials Market: Quality Assurance
  • FIG. 5 Global RNA Therapy Clinical Trials Market, By Modality, 2022
  • FIG. 6 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022
  • FIG. 7 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022
  • FIG. 8 Global RNA Therapy Clinical Trials Market, By Geography, 2022
  • FIG. 9 Market Geographical Opportunity Matrix - Global RNA Therapy Clinical Trials Market, 2022

FIG. 10Market Positioning of Key RNA Therapy Clinical Trials Market Players, 2022

FIG. 11Global RNA Therapy Clinical Trials Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031

  • FIG. 12 Global RNA Therapy Clinical Trials Market, By Modality, 2022 Vs 2031, %
  • FIG. 13 Global RNA Therapy Clinical Trials Market, By Clinical Trials Phase, 2022 Vs 2031, %
  • FIG. 14 Global RNA Therapy Clinical Trials Market, By Therapeutic Areas, 2022 Vs 2031, %
  • FIG. 15 U.S. RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 16 Canada RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 17 Rest of North America RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 18 UK RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 19 Germany RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 20 Spain RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 21 Italy RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 22 France RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 23 Rest of Europe RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 24 China RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 25 Japan RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 26 India RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 27 Australia RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 28 South Korea RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 29 Rest of Asia RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 30 Brazil RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 31 Mexico RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 32 Rest of Latin America RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 33 GCC RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 34 Africa RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031
  • FIG. 35 Rest of Middle East and Africa RNA Therapy Clinical Trials Market (US$ Million), 2021 - 2031